145 related articles for article (PubMed ID: 28258132)
1. Mortality in Graves' orbitopathy is increased and influenced by gender, age and pre-existing morbidity: a nationwide Danish register study.
Schwensen CF; Brandt F; Hegedüs L; Brix TH
Eur J Endocrinol; 2017 Jun; 176(6):669-676. PubMed ID: 28258132
[TBL] [Abstract][Full Text] [Related]
2. Death by Suicide in Graves' Disease and Graves' Orbitopathy: A Nationwide Danish Register Study.
Ferløv-Schwensen C; Brix TH; Hegedüs L
Thyroid; 2017 Dec; 27(12):1475-1480. PubMed ID: 29084476
[TBL] [Abstract][Full Text] [Related]
3. Hyperthyroid patients without Graves' orbitopathy are not at increased risk of developing glaucoma: a nationwide Danish register-based case-control study.
Brandt F; Thvilum M; Hegedüs L; Brix TH
Endocrine; 2018 Jan; 59(1):137-142. PubMed ID: 29198022
[TBL] [Abstract][Full Text] [Related]
4. Graves' disease and toxic nodular goiter are both associated with increased mortality but differ with respect to the cause of death: a Danish population-based register study.
Brandt F; Thvilum M; Almind D; Christensen K; Green A; Hegedüs L; Brix TH
Thyroid; 2013 Apr; 23(4):408-13. PubMed ID: 23253072
[TBL] [Abstract][Full Text] [Related]
5. Clinical Implications of Immunoglobulin G4 to Graves' Ophthalmopathy.
Yu SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Thyroid; 2017 Sep; 27(9):1185-1193. PubMed ID: 28805160
[TBL] [Abstract][Full Text] [Related]
6. Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy.
Marinò M; Rotondo Dottore G; Ionni I; Lanzolla G; Sabini E; Ricci D; Sframeli A; Mazzi B; Menconi F; Latrofa F; Vitti P; Marcocci C; Chiovato L
J Endocrinol Invest; 2019 Apr; 42(4):471-480. PubMed ID: 30132285
[TBL] [Abstract][Full Text] [Related]
7. Serum selenium status in Graves' disease with and without orbitopathy: a case-control study.
Khong JJ; Goldstein RF; Sanders KM; Schneider H; Pope J; Burdon KP; Craig JE; Ebeling PR
Clin Endocrinol (Oxf); 2014 Jun; 80(6):905-10. PubMed ID: 24372054
[TBL] [Abstract][Full Text] [Related]
8. Type 2 diabetic patients with Graves' disease have more frequent and severe Graves' orbitopathy.
Le Moli R; Muscia V; Tumminia A; Frittitta L; Buscema M; Palermo F; Sciacca L; Squatrito S; Vigneri R
Nutr Metab Cardiovasc Dis; 2015 May; 25(5):452-7. PubMed ID: 25746910
[TBL] [Abstract][Full Text] [Related]
9. Comparative assessment of gut microbial composition and function in patients with Graves' disease and Graves' orbitopathy.
Shi TT; Xin Z; Hua L; Wang H; Zhao RX; Yang YL; Xie RR; Liu HY; Yang JK
J Endocrinol Invest; 2021 Feb; 44(2):297-310. PubMed ID: 32449092
[TBL] [Abstract][Full Text] [Related]
10. Statins Decrease the Risk of Orbitopathy in Newly Diagnosed Patients with Graves Disease.
Nilsson A; Tsoumani K; Planck T
J Clin Endocrinol Metab; 2021 Apr; 106(5):1325-1332. PubMed ID: 33560351
[TBL] [Abstract][Full Text] [Related]
11. The potential markers involved in newly diagnosed graves' disease and the development of active graves' orbitopathy.
He M; Wang Y; Wang J; Sui J; Ding X; Chen Z; Zhang M; Zhao Y; Xie B; Shi B
Cytokine; 2020 Mar; 127():154998. PubMed ID: 31972501
[TBL] [Abstract][Full Text] [Related]
12. Sex-specific risk factors associated with graves' orbitopathy in Korean patients with newly diagnosed graves' disease.
Lee J; Kang J; Ahn HY; Lee JK
Eye (Lond); 2023 Nov; 37(16):3382-3391. PubMed ID: 37041348
[TBL] [Abstract][Full Text] [Related]
13. Knowledge of Thyroid Eye Disease in Graves' Disease Patients With and Without Orbitopathy.
Edmunds MR; Boelaert K
Thyroid; 2019 Apr; 29(4):557-562. PubMed ID: 30688164
[TBL] [Abstract][Full Text] [Related]
14. Incidence and clinical presentation of moderate to severe graves' orbitopathy in a Danish population before and after iodine fortification of salt.
Laurberg P; Berman DC; Bülow Pedersen I; Andersen S; Carlé A
J Clin Endocrinol Metab; 2012 Jul; 97(7):2325-32. PubMed ID: 22518849
[TBL] [Abstract][Full Text] [Related]
15. Incidence and risk factors for Graves' orbitopathy in patients who underwent anti-inflammatory and immunosuppressive treatment during medical treatment for Graves' disease: investigation of 1,553 cases with newly diagnosed Graves' disease and proposal of a predictive score.
Watanabe N; Yoshimura Noh J; Kozaki A; Yoshimura R; Yoshihara A; Suzuki N; Matsumoto M; Fukushita M; Kinoshita A; Aida A; Imai H; Hiruma S; Inoue T; Inoue K; Sugino K; Ito K
Endocr J; 2023 Nov; 70(11):1087-1096. PubMed ID: 37743517
[TBL] [Abstract][Full Text] [Related]
16. Serum selenium status in Egyptians patients who had Graves' disease with and without ophthalmopathy.
Hasanin GA; Mohamed MS; Maher MM; Ahmed AM; ALi HM; Mansour HK
Egypt J Immunol; 2024 Jan; 31(1):133-142. PubMed ID: 38224470
[TBL] [Abstract][Full Text] [Related]
17. Nicotinamide phosphoribosyltransferase leukocyte overexpression in Graves' opthalmopathy.
Sawicka-Gutaj N; Budny B; Zybek-Kocik A; Sowiński J; Ziemnicka K; Waligórska-Stachura J; Ruchała M
Endocrine; 2016 Aug; 53(2):497-504. PubMed ID: 26767650
[TBL] [Abstract][Full Text] [Related]
18. Increased Cardiovascular Mortality and Morbidity in Patients Treated for Toxic Nodular Goiter Compared to Graves' Disease and Nontoxic Goiter.
Giesecke P; Rosenqvist M; Frykman V; Friberg L; Wallin G; Höijer J; Lönn S; Törring O
Thyroid; 2017 Jul; 27(7):878-885. PubMed ID: 28471268
[TBL] [Abstract][Full Text] [Related]
19. Raising awareness of Graves' orbitopathy with early warning cards.
Mitchell AL; Hickey J; Vaidya B; Mason R; Ajjan R; Zammitt N; Perros P; Dayan C;
Clin Endocrinol (Oxf); 2017 Dec; 87(6):853-859. PubMed ID: 28755510
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of IL-29 in Euthyroid Patients with Graves' Orbitopathy: A Preliminary Study.
Falkowski B; Szczepanek-Parulska E; Sawicka-Gutaj N; Krygier A; Ruchala M
Mediators Inflamm; 2020; 2020():4748612. PubMed ID: 32694926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
